top of page

effectively maintains pupil dilation

and requires less use of PEDs¹⁻⁶

Reduces complications

such as IFIS, CME, and breakthrough iritis⁷⁻⁸

improveS patient experience

with less pain, greater visual acuity, and fewer to no drops¹⁻²˒⁸˒¹¹

OMIDRIA blocks the inflammatory cascade before it starts and leads to positive patient outcomes

Stay ahead of the unexpected

OMIDRIA, the only FDA-approved intracameral NSAID

OMIDRIA is the 1st and only FDA-approved non-opioid, NSAID-containing treatment for maintaining pupil size and reducing postoperative pain by preventing intraoperative miosis.¹

  • 96% of OMIDRIA-treated patients had pupil diameter ≥6 mm at the start of lens implantation¹˒¹³˒²⁰

  • Real-world evidence shows that OMIDRIA can benefit ALL patient types, not just high-risk patients²˒⁴⁻⁸˒¹⁷˒¹⁹

OMIDRIA effectively maintains pupil dilation